Editorial: HIV drug design

Current Pharmaceutical Design

Volumn 12, Issue 16, 2006, Pages 1941-1942

  Bourinbaiar, Aldar S ^a  

^a Immunitor USA Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTISENSE OLIGONUCLEOTIDE; BLEOMYCIN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYCLIN DEPENDENT KINASE INHIBITOR; DEFERIPRONE; DEFEROXAMINE; FLAVOPIRIDOL; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IRON CHELATING AGENT; RIBOZYME; RNA POLYMERASE II; ROSCOVITINE; SMALL INTERFERING RNA; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLOIMMUNIZATION; ANTIBACTERIAL ACTIVITY; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG CHOICE; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; EDITORIAL; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TUBERCULOSIS; VIRUS GENOME; VIRUS IMMUNITY; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 33744758034     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777442128     Document Type: Editorial

References (7)

1. Meyer D. Iron chelation as therapy for HIV and Mycobacterium tuberculosis co-infection under conditions of iron overload. Curr Pharm Design 2006; 12(16): 1943-1947.
2. Pumfery A, de la Fuente C, Berro R, Nekhai S, Kashanchi F, Chao S-H. Potential Use of Pharmacological Cyclin-Dependent Kinase Inhibitors as Anti-HIV Therapeutics. Curr Pharm Design 2006; 12(16): 1949-1961.
3. Pöhlmann S, Reeves JD. Cellular entry of HIV: Evaluation of therapeutic targets. Curr Pharm Design 2006; 12(16): 1963-1973.
4. Varier RA, Kundu TK. Chromatin modifications (Acetylation/ Deacetylation/ Methylation) as new targets for HIV therapy. Curr Pharm Design 2006; 12(16): 1975-1993.
5. Christopher ME, Wong JP. Recent developments in delivery of nucleic acid-based antiviral agents. Curr Pharm Design 2006; 12(16): 1995-2006.
6. Bregenholt S, Jensen A, Lantto J, Hylding S, Haurum. J. Recombinant human polyclonal antibodies: a new class of therapeutic antibodies against viral infections. Curr Pharm Design 2006; 12(16): 2007-2015.
7. Bourinbaiar AS, Root-Bernstein RS, Abulafia-Lapid R, Rytik PG, Kanev AN, Jirathitikal V, Orlovsky VG. Therapeutic AIDS vaccines. Curr Pharm Design 2006; 12(16): 2017-2030.